Schiele B C
Dis Nerv Syst. 1975 Jul;36(7):361-4.
Loxapine succinate was compared to chlorpromazine in a 12-week double-blind study of 50 hospitalized chronic schizophrenic patients. Statistical analyses of BPRS scores showed significant improvemement for several items and factors in both groups of patients. Both drugs significantly decreased severity of illness on the CGI scale. On the NOSIE scale, "manifest psychosis" was improved significantly with chlorpromazine and "global severity" with loxapine succinate. There were no significant treatment differences in BPRS, CGI, or Nosie items or factors or in the reduction of overall psychopathology. The side effects associated with the study drugs differed little with respect to incidence, number, severity, and type. The most frequently reported symptoms in both groups were behavioral, extrapyramidal, and sedative. Analyses of vital signs and clinical laboratory data revealed no evidence of serious untoward effects.
在一项针对50名住院慢性精神分裂症患者的为期12周的双盲研究中，对琥珀酸洛沙平与氯丙嗪进行了比较。对简明精神病评定量表（BPRS）评分的统计分析表明，两组患者的几个项目和因子都有显著改善。两种药物在临床总体印象量表（CGI）上均显著降低了疾病严重程度。在护士观察量表（NOSIE）上，氯丙嗪使“明显精神病症状”显著改善，琥珀酸洛沙平使“总体严重程度”显著改善。在BPRS、CGI或NOSIE项目、因子或总体精神病理学减轻方面，治疗差异均无统计学意义。与研究药物相关的副作用在发生率、数量、严重程度和类型方面差异不大。两组最常报告的症状是行为、锥体外系和镇静方面的症状。对生命体征和临床实验室数据的分析未发现严重不良影响的证据。
